The perspectives and challenges in BRAF-mutant advanced melanoma

被引：0
|
作者：
Romanova, Alexandra [1 ]
Balandina, Anastasiia [2 ]
机构：
[1] Albert Ludwigs Univ Freiburg, Med Fak, Freiburg, Germany
[2] Heidelberg Univ, Med Fak, Heidelberg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2022年 / 20卷
关键词：
IMMUNOTHERAPY;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P082
引用
收藏
页码：45 / 45
页数：1
相关论文
共 50 条
  • [21] BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma
    Liu, Qi
    Zhu, Hongda
    Liu, Yun
    Musetti, Sara
    Huang, Leaf
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (02) : 299 - 310
  • [22] BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma
    Paoluzzi, Luca
    Hanniford, Douglas
    Sokolova, Elena
    Osman, Iman
    Darvishian, Farbod
    Wang, Jinhua
    Bradner, James E.
    Hernando, Eva
    [J]. CANCER MEDICINE, 2016, 5 (06): : 1183 - 1193
  • [23] Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
    Tarhini, Ahmad
    McDermott, David
    Ambavane, Apoorva
    Gupte-Singh, Komal
    Aponte-Ribero, Valerie
    Ritchings, Corey
    Benedict, Agnes
    Rao, Sumati
    Regan, Meredith M.
    Atkins, Michael
    [J]. IMMUNOTHERAPY, 2019, 11 (04) : 283 - 295
  • [24] BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
    Bai, X.
    Mao, L. L.
    Chi, Z. H.
    Sheng, X. N.
    Gui, C. L.
    Kong, Y.
    Dai, J.
    Wang, X.
    Li, S. M.
    Tang, B. X.
    Lian, B.
    Zhou, L.
    Yan, X. Q.
    Guo, J.
    Si, L.
    [J]. NEOPLASMA, 2017, 64 (04) : 626 - 632
  • [25] Treatment Sequencing in Advanced BRAF-Mutant Melanoma Patients: Current Practice in the United States
    Audibert, Celine
    Stuntz, Mark
    Glass, Daniel
    [J]. JOURNAL OF PHARMACY TECHNOLOGY, 2018, 34 (01) : 17 - 23
  • [26] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
    Paolo Antonio Ascierto
    Pier Francesco Ferrucci
    Rosalie Fisher
    Michele Del Vecchio
    Victoria Atkinson
    Henrik Schmidt
    Jacob Schachter
    Paola Queirolo
    Georgina V. Long
    Anna Maria Di Giacomo
    Inge Marie Svane
    Michal Lotem
    Gil Bar-Sela
    Felix Couture
    Bijoyesh Mookerjee
    Razi Ghori
    Nageatte Ibrahim
    Blanca Homet Moreno
    Antoni Ribas
    [J]. Nature Medicine, 2019, 25 : 941 - 946
  • [27] Which drug, and when, for patients with BRAF-mutant melanoma?
    Jang, Sekwon
    Atkins, Michael B.
    [J]. LANCET ONCOLOGY, 2013, 14 (02): : E60 - E69
  • [28] Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice
    Mangana, Joanna
    Zihler, Deborah
    Bossart, Simon
    Broennimann, Daniel
    Zachariah, Ralph
    Gerard, Camille Lea
    [J]. MELANOMA RESEARCH, 2022, 32 (05) : 366 - 372
  • [29] What Is Optimal First-Line Treatment of Unresectable or Advanced BRAF-Mutant Melanoma?
    Atkins, Michael B.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (06) : 417 - 419
  • [30] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
    Ascierto, Paolo Antonio
    Ferrucci, Pier Francesco
    Fisher, Rosalie
    Del Vecchio, Michele
    Atkinson, Victoria
    Schmidt, Henrik
    Schachter, Jacob
    Queirolo, Paola
    Long, Georgina V.
    Di Giacomo, Anna Maria
    Svane, Inge Marie
    Lotem, Michal
    Bar-Sela, Gil
    Couture, Felix
    Mookerjee, Bijoyesh
    Ghori, Razi
    Ibrahim, Nageatte
    Moreno, Blanca Homet
    Ribas, Antoni
    [J]. NATURE MEDICINE, 2019, 25 (06) : 941 - +
12345